Jump to navigation Jump to search
Clinical data
Routes of
Oral, Intravenous, Vaporized, Insufflated, Suppository
Legal status
Legal status
Pharmacokinetic data
Elimination half-life8 hours
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass177.2456

Phenmetrazine is a stimulant of the central nervous system. It was previously sold under the trade name Preludin as an anorectic. Preludin has since been removed from the market. It was initially replaced by the weaker analogue Phendimetrazine (Bontril), but this is now only rarely prescribed, due to problems with abuse.

Other names that have been used for Phenmetrazine include: Defenmetrazin, Fenmetrazin, Oxazimedrine, Phenmetraline.


It was first patented in Germany in 1952 by Boehringer-Ingelheim. It was the result of a search by Thomae and Wick for an anorectic substance without the side-effects of amphetamine[1] . Phenmetrazine was introduced into clinical use in 1954 in Europe[2] .

Medical use

In clinical use phenmetrazine produces less nervousness, hyperexcitability, euphoria and insomnia than the amphetamines[3]. It doesn't tend to increase the pulse either[1]. Due to the relative lack of side-effects, one study found it well tolerated in children[1]. In a study of the effectiveness on weight loss between phenmetrazine and dextroamphetamine, phenmetrazine was found to be slightly more efficient[4].

Even though the manufacturers claimed it had "exceptional safety and strikingly low incidence of side effects", within some years there were some reports of psychotic reactions of the amphetamine type[2].


Phenmetrazine produces its action by causing release of noradrenaline and dopamine in the central nervous system[5].

After an oral dose, about 70% of the drug is excreted from the body within 24 hours. About 19% of that is excreted as the unmetabolised drug and the rest as various metabolites[6]

In trials in rats it has been found that after subcutaneous administration, both the optical isomers of phenmetrazine is equally effective in reducing food intake, but in oral administration the levo isomer is more effective. In terms of central stimulation however, the dextro isomer is about 4 times as effective in both methods of administration[7].


It is by some considered to have a greater potential for addiction than the amphetamines, and has been abused in many countries, for example Sweden. When stimulant abuse first became prevalent in Sweden in the 1950s, phenmetrazine was preferred to amphetamine and methamphetamine by addicts, as it was considered the superior drug. In the autobiographical novel "Rush" by Kim Wozencraft, intravenous phenmetrazine is described as the most euphoric and pro-sexual of the stimulants the author used.

Phenmetrazine was classified as a narcotic in Sweden in 1959, and was taken completely off the market in 1965. At first the illegal demand was satisfied by smuggling from Germany and later Spain and Italy. At first Preludin tablets were smuggled, but soon the smugglers started bringing in raw phenmetrazine powder. Eventually Amphetamine became the dominant stimulant of abuse because of its easier availability.

The drug was taken by The Beatles early in their career. Paul McCartney was one known user. McCartney's introduction to drugs started in Hamburg, Germany. The Beatles had to play for hours, and they were often given "Prellies" (Preludin) by German customers or by Astrid Kirchherr (whose mother bought them). McCartney would usually take one, but John Lennon would often take four or five.[8]


  1. 1.0 1.1 1.2 Martel, Antonio (1957). "Preludin (Phenmetrazine) in the Treatment of Obesity". Can. Med. Assoc. J. 76: 117.
  2. 2.0 2.1 Kalant, Oriana Josseau (1966). The Amphetamines: Toxicity and Addiction.
  3. "Phenmetrazine Hydrochloride". J. Am. Med. Assoc. 163 (5): 357. 1957.
  4. Hampson, J (1960). "Phenmetrazine and Dexamphetamine in the Management of Obesity". The Lancet. 275 (7137): 1265.
  5. Rothman RB; et al. (2002). "Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain". Eur J Pharmacol. 447 (1): 51.Abstract
  6. Anthony C Moffat, M David Osselton and Brian Widdop. Clarke's Analysis of Drugs and Poisons. ISBN 0-85369-473-7.
  7. Engelhardt, A (1961). "Studies of the Mechanism of the Anti-Appetite Action of Phenmetrazine". Biochem. Pharmacol. 8 (1): 100.
  8. Miles 1998. pp66-67.


da:Preludin sv:Fenmetrazin

Template:WikiDoc Sources